Introduction
============

Hepatitis C virus (HCV) infects over 200 million people.^[@bib1]^ Spontaneous clearance of HCV infection is largely affected by variants of the interferon lambda 3 (*IFNL3*) gene.^[@bib2]^ Failure to clear leads to chronic hepatitis C (CHC), which can result in significant complications including liver cirrhosis, hepatocellular carcinoma and death from liver failure, as well as other immune-related phenomena such as cryoglobulinaemia and lymphoma.^[@bib3]^

In 2009, three landmark genome-wide association studies (GWAS) identified a set of single-nucleotide polymorphisms (SNPs) in the vicinity of the *IFNL3* gene, which were significantly associated with clearance of genotype 1 HCV on conventional therapy.^[@bib4],\ [@bib5],\ [@bib6]^ Subsequently, this genetic variation has been strongly associated with spontaneous clearance of HCV.^[@bib2]^ In 2013, a new polymorphism (ss469415590) between IFNL2 and IFNL3 was identified and found to induce a frameshift mutation, resulting in transient expression of an IFN analogue, IFN lambda 4 (IFNL4), in stimulated human hepatocytes.^[@bib7]^ The genotype-dependent production of the protein IFNL4 resulted in altered IFN-sensitive gene (ISG) expression and thus may explain the effects on viral clearance. ss469415590 is in high linkage disequilibrium with *rs12979860* but more strongly associated with spontaneous and treatment-induced HCV clearance. We have referred to the SNPs *rs12979860* and *rs8099917* as IFNL3 SNPs in this paper, although they could also be referred to as being from the gene *IFNL4*.

IFNL3, a member of the type III IFN family, induces potent innate anti-viral effects against a number of viruses including HCV.^[@bib8],\ [@bib9],\ [@bib10],\ [@bib11]^ Its effects are mediated via signalling through the interferon lambda receptor 1 (IFNLR1) complex, whose expression has been confirmed on a variety of cells including lymphocytes.^[@bib8],\ [@bib12],\ [@bib13]^ There are at least two splice variants of the IFNLR1 receptor chain: a membrane-associated receptor (IFNLR1-mem) and a truncated soluble receptor (IFNLR1-sol), which lacks the transmembrane domain. It has therefore been speculated that the soluble receptor acts as a negative regulator of type III IFNs by binding to the cytokines before cell contact.^[@bib14]^ However, soluble receptors can also increase signalling by increasing cytokine half-life^[@bib15]^ or potentiating signalling.^[@bib16]^

The host immune response is pivotal to a successful outcome at initial infection, during and after development of CHC. A strong virus-specific cytotoxic response, largely mediated by CD4 T helper type 1 (Th1) cells and natural killer (NK) cells, is required to remove infected hepatocytes, secrete cytokines and promote hepatocyte production of ISGs that allow for the inhibition of viral replication.^[@bib17]^ In contrast, there is some evidence to suggest that a CD4 Th2-dominant response is associated with HCV treatment failure and viral persistence.^[@bib18],\ [@bib19]^ The anti-viral role of CD8 T cells in CHC is thought to be negligible.^[@bib20]^

We hypothesised that *IFNL3* genotype may mediate differences in the immunological phenotype in CHC. To test our hypothesis, we initially analysed a large cross-sectional cohort of genotype 1 CHC subjects, then performed a flow cytometric analysis on a cohort of 67 of these. Analysis was also performed on transcription factors, as the master regulators of Th cell and NK differentiation and mediators of the immune response, including: TBX21 (Th1, NK cells), GATA3 (Th2), RORC (Th17), FOXP3 (T-regulatory cells (Tregs)) and EOMES (CD8, NK cells).^[@bib21]^ Finally, we also assessed the expression of IFNL3-associated genes (*IFNL3*, *IFNLR1*, *IFNLR1-mem*, *IFNLR1-sol* and *MxA*). These data provide evidence of *IFNL3* genotype-associated monocyte, T- and NK cell alterations in peripheral blood, which could be due to variation in immune cell trafficking to the infected liver, and may explain the genetic associations with viral clearance, necroinflammation and response to therapy.

Results
=======

Haematological markers correlate with *IFNL3* genotype and HCV viral load
-------------------------------------------------------------------------

The baseline characteristics of the 400 patients according to *IFNL3* genotypes are summarised in [Table 1](#tbl1){ref-type="table"}. No significant difference between the groups was observed for age or gender. At baseline, a number of highly significant haematological differences between the *IFNL3* genotypes were detected ([Table 1](#tbl1){ref-type="table"}). The *IFNL3* responder genotype groups demonstrated lower baseline white blood cell (WBC) count (*rs8099917 P=*2.8 × 10^−4^ and *rs12979860 P=*2.8 × 10^−3^), absolute lymphocyte count (ALC) (*rs8099917* *P=*5.0 × 10^−3^ and *rs12979860 P=*0.015), absolute neutrophil count (ANC) (*rs8099917* *P=*0.013 and *rs12979860 P=*0.022) and absolute monocyte count (AMC) (*rs8099917* *P=*6.1 × 10^−4^ and *rs12979860 P=*0.021). An association with lower haemoglobin was also observed, but only for *rs8099917*. There was no significant difference in platelet counts between the *IFNL3* genotypes.

HCV viral load measurements were stratified into high (⩾8.5 × 10^5^ IU ml^−1^) and low (\<8.5 × 10^5 ^IU ml^−1^) viral load groups. A significantly higher proportion of *IFNL3* responder genotypes were observed in the high viral load group compared with the low viral load group (*rs8099917*: 35% low viral load vs 61% high viral load, *P=*0.0007 and *rs12979860*: 16% low viral load vs 50% high viral load, *P\<*0.0001). The high viral load group demonstrated lower WBCs (*P=*0.034) and ALC (*P=*0.034) ([Table 2](#tbl2){ref-type="table"}).

Flow cytometric deconvolution of leucocytes confirms genotype effect
--------------------------------------------------------------------

Flow cytometric analysis of peripheral blood mononuclear cells from 67 CHC patients before therapy indicated a reduction in monocytes (*P\<*0.05) in the *rs12979860* responder genotype ([Figure 1a](#fig1){ref-type="fig"}). Further subsetting demonstrated a reduction in CD56 high NK cells (*P\<*0.05), and a similar trend in CD4+ T cells, as indicated by a reduced CD4/CD8 ratio (*P=*0.054). Responder genotypes also had a lower proportion of RO+ to RO− in both CD4 and CD8 subsets (*P\<*0.001, *P=*0.08, respectively).

Transcription factor expression in peripheral blood in CHC
----------------------------------------------------------

As CD4CD45RO T and NK cells are thought to mediate viral clearance, we assessed their abundance in peripheral blood by measuring cell subset-specific transcription factors.^[@bib22],\ [@bib23]^ Comparison was made for transcription factors *FOXP3*, *GATA3*, *RORC* and *TBX21* between CHC cohort (*n=*24) and healthy controls (*n=*22). A significantly higher expression (*P=*0.04) of circulating FOXP3 cells were detected in CHC cohort compared with healthy controls ([Figure 2](#fig2){ref-type="fig"}).

No significant correlation between *IFNL3* genotype and transcription factor expression was detected in CHC. As Th1 and NK cells facilitate viral clearance, we hypothesised that the *IFNL3* responder genotype would have a Th1, NK-dominant phenotype. To identify relative differences within the lymphocyte population, we used ratios to compare Th1, NK (TBX21) to the other subsets: Th2 (GATA3), Th17 (RORC) and Treg (FOXP3). In addition, as the transcription factors are variably expressed, we used their rank across sample rather than their absolute expression values. For *rs8099917*, we found a significant association with a *TBX21* (Th1/NK)-dominant effect: *TBX21*/*GATA3* (Th1, NK/Th2: *P=*0.017); *TBX21/RORC* (Th1, NK/Th17: *P=*7.4 × 10^−3^) and *TBX21/FOXP3* (Th1, NK:Treg: *P=*0.036), with the ratio higher for responders in each case. For *rs12979860*, the same trend was also observed and this was significant for: *TBX21*/*GATA3* (Th1, NK/Th2: *P=*0.038) and *TBX21/RORC* (Th1, NK/Th17: *P=*5.2 × 10^−3^) ([Figure 3](#fig3){ref-type="fig"}). In other works,^[@bib24]^ we have confirmed that the expression of these genes is highest in these subsets.

*IFNLR1* and *MxA* mRNAs are increased in peripheral blood in CHC
-----------------------------------------------------------------

*IFNL3*, *IFNLR1 and MxA* expression was measured in peripheral blood samples from healthy controls (*n=*22) and HCV-infected untreated subjects (*n=*24). CHC patients demonstrated significantly higher expression levels of *MxA* (*P=*3.0 × 10^−6^) ([Figure 4e](#fig4){ref-type="fig"}), *IFNLR1* (*P*=3.2 × 10^−12^) ([Figure 4b](#fig4){ref-type="fig"}), *IFNLR1-mem* (*P=*0.041) ([Figure 4c](#fig4){ref-type="fig"}) and *IFNLR1-sol* (*P=*3.0 × 10^−3^) ([Figure 4d](#fig4){ref-type="fig"}) compared with healthy controls. However, no difference in *IFNL3 mRNA* expression was detected between untreated HCV-infected subjects and healthy controls ([Figure 4a](#fig4){ref-type="fig"}). We looked for an association between *IFNL3* genotype and expression levels of *IFNL3*, *IFNLR1*, *IFNLR1-sol*, *IFNLR1-mem* and *MxA* in untreated CHC subjects. There was a trend towards higher baseline expression of all five parameters measured (*IFNL3*, *IFNLR1*, *MxA*, *IFNLR1-sol* and *IFNLR1-mem*) compared with those with the *IFNL3* responder genotypes (*rs809917* TT and *rs12979860* CC). However, this only reached statistical significance for *IFNLR1-sol* (*rs809917*: *P=*0.02).

Discussion
==========

In this study, we sought to define *IFNL3* genotype effects on peripheral blood immune cells to improve our understanding of the basis *IFNL3* genotype-associated differences in viral clearance. We demonstrate, for the first time, significantly lower baseline total white cell, neutrophil, lymphocyte and monocyte counts for people with *IFNL3* responder genotypes (for both *rs8099917* and *rs12979860*) and an association between higher pre-treatment viral load and lower white cell and lymphocyte counts. From flow cytometric analysis, responder genotypes had a lower CD56 high/dim ratio, lower CD45RO+/− ratio and fewer monocytes. The IFN-sensitive genes *MxA* and *IFNLR* (sol- and membrane-bound isoforms) were higher in CHC compared with that in controls, but IFNL3 was not. For responders for all genes there was a trend for higher expression.

Further, in patients with *IFNL3* responder genotype, transcription factor analysis revealed evidence for a Th1/NK-dominant state in peripheral blood. Taken together, these results suggest that in individuals with the *IFNL3* responder genotype there may be increased lymphocyte redistribution to the liver and secondary lymphoid organs, resulting in increased priming and activation of adaptive immune cells. On treatment with exogenous IFNA, the Th1/NK-dominant response increased immune cell activation and immune cell residency in the liver would favour rapid viral clearance and may explain *IFNL3* genotype-associated associations with rapid virological response and sustained virological response.

Lymphopenia is associated with viral infections and others have shown that this is related to redistribution of lymphocytes to secondary lymphoid organs^[@bib25]^ and increased lymphocyte tissue residency time.^[@bib26]^ This lymphocyte redistribution is mediated, in part, by endogenous type I IFNs in viral infection.^[@bib27]^ Cirrhosis is also associated with haematologic abnormalities including varying degrees of cytopenias. However, in neither instance has this been observed to relate to type III IFN genotype. Moreover, in cirrhosis, thrombocytopenia is the most commonly detected abnormality, with low WBCs and anaemia tending to develop later in the disease course.^[@bib28]^ In our study, we saw no consistent association of platelet counts or haemoglobin with *IFNL3* genotype, suggesting a targeted effect on immune cell activation and trafficking. Thus, our data suggest an *IFNL3* genotype-specific altered immune state and blood profile, likely triggered by chronic viral infection and endogenous IFNs.

In support of this contention, we demonstrate evidence of endogenous activation of the peripheral blood compartment by the IFN system in CHC. Significantly higher levels of *MxA* have been described previously,^[@bib29]^ and here we additionally show that expression of *IFNLR1*, *IFNLR1-mem* and *IFNLR1-sol* are also elevated in infected patients compared with healthy controls. Interestingly, we did not observe higher expression levels for *IFNL3* mRNA in HCV-infected subjects, compared with controls. IFNL3 production is produced by rare immune cell subsets, including BDCA3 dendritic cells and plasmacytoid dendritic cells, as we and others have previously demonstrated.^[@bib13],\ [@bib30]^ It is therefore possible that differences in production of IFNL3 between healthy controls and CHC subjects may be only detectable by analysing these immune cell subsets.

In relation to *IFNL3* genotype, we observed higher ISG expression in the peripheral blood of patients with the responder genotype, using *MxA* as the candidate ISG. Patients with the *IFNL3* responder genotype have been shown to express more IFNL3, yet demonstrate lower hepatic ISG expression compared with non-responders at baseline.^[@bib31],\ [@bib32],\ [@bib33]^ Taken together, these data suggest that IFNL3 may act predominantly on immune cells to facilitate HCV clearance in these individuals.

Since the publication of genome-wide association studies in 2009 identifying SNPs in the vicinity of *IFNL3* associated with response to treatment in CHC, there has been an intense research effort to determine the molecular basis for the genotype effect. A number of significant advances have been reported, including replicated associations of the favourable *IFNL3* genotype with lower hepatic ISG expression,^[@bib31],\ [@bib32],\ [@bib33]^ increased hepatic necroinflammation,^[@bib34],\ [@bib35],\ [@bib36],\ [@bib37]^ higher baseline viral load^[@bib4],\ [@bib38],\ [@bib39]^ and increased rates of rapid virological response/early virological response.^[@bib40],\ [@bib41],\ [@bib42],\ [@bib43]^ However, the basis for these associations remains largely conjectural. An altered host immune state linked to the *IFNL3* polymorphism may result in a Th1/NK-dominant response to HCV infection. Although Th1/NK cytokines favour viral clearance, they are likely to also have a role in mediating hepatocellular damage, if clearance is not achieved. Among the Th1/NK cytokines interleukin-2, IFN-γ and tumour necrosis factor-α have been shown to mediate tissue injury,^[@bib17]^ whereas high levels have been associated with lymphopenia, particularly T-cell lymphopenia.^[@bib27]^ Those with the responder genotype have fewer effectors T cells, fewer NK CD56 bright than dim and lower monocyte counts, which may be due to increased trafficking or redistribution of these cells to the liver and secondary lymphoid tissues, resulting in increased priming and activation of adaptive immune cells. Following treatment with exogenous IFNA, the milieu in *IFNL3* responder genotype individuals renders them primed for viral clearance. This is particularly the case as IFNL3 has the ability to modulate Tregs and enhance the adaptive cellular response through induction of Th1-biased responses.^[@bib44]^

Our study has several limitations, including the small number of patients with detailed kinetic and transcription factor analysis. Further, the observed genotype associations with transcription factor ratios may be driven by immune cells other than those from which their expression was expected. The Th subset (Th1, Th2, Treg and Th17) and NK findings should ultimately be confirmed with cytokine and flow cytometric analysis of peripheral blood. Ideally, but perhaps unrealistically, paired liver biopsies would be required to validate our hypothesis of altered cell trafficking to the liver in *IFNL3* genotypes, but the recent report by Honda *et al.*^[@bib45]^ suggests that this is indeed the case. Interestingly, a recent genome-wide association study subanalysis from the Individualized Dosing Eficacy vs. Flat Dosing to Assess Optimal Pegylated Interferon Therapy (IDEAL) study,^[@bib41]^ performed to detect SNPs associated with cytopenias during treatment, failed to detect any association with *IFNL3* genotypes.^[@bib46]^ There is some evidence that this cohort had less advanced liver disease compared with our patients, including milder fibrosis, higher platelet counts and younger age (summarised in [Supplementary Table 2](#sup1){ref-type="supplementary-material"}). In addition, there were a number of exclusion criteria in the IDEAL study (including low pre-treatment ANC, platelet and haemoglobin), which did not apply to our patient population, and it is known that lower WBCs and anaemia tend to develop later in the disease course.^[@bib28]^ Thus, the *IFNL3* genotype effect we observed may be cohort-dependent and requires replication.

In summary, we observed an altered pre-treatment immune state in the peripheral blood of patients with genotype 1 CHC, with reduced numbers of WBC, ANC, ALC and ANC and a Th1/NK bias in the *IFNL3* responder genotypes. Compared with controls, CHC subjects demonstrated evidence of endogenous IFN activation with higher expression levels of *MxA*, *IFNLR1*, *IFNLR1-mem* and *IFNLR1-sol*, but not *IFNL3*. These novel and highly significant associations with *IFNL3* genotype strengthen support for an immune cell-mediated foundation for the molecular basis of this genotype effect.

Materials and methods
=====================

Study cohort
------------

The three study cohorts consisted of Caucasian subjects with genotype 1 HCV infection (summarised in [Figure 5](#fig5){ref-type="fig"}). Briefly, baseline haematological data were collected on an initial cohort of 400 subjects (Cohort 1). HCV viral load measurements were also available for 171 of these subjects. From Cohort 1, 67 subjects (Cohort 2) were studied with a flow cytometric panel. Expression of a panel of genes was undertaken for 24 of these subjects (Cohort 3) using PAXgene Blood RNA tubes (Qiagen, Valencia, CA, USA). In addition, PAXgene Blood RNA tubes were collected from 22 age-matched healthy Caucasian controls for comparison.

Ethics statement
----------------

Ethical approval was obtained from the Human Research Ethics Committees of the Sydney West Area Health Service and the University of Sydney. All subjects gave written informed consent (HREC2002/12/4.9(1564)).

Flow cytometry
--------------

Venous blood was collected in EDTA and peripheral blood mononuclear cells isolated on Ficoll-Paque Plus (VWR International, Brisbane, QLD, Australia), washed in phosphate-buffered saline and cryopreserved in RPMI-1640 medium (Life Technologies, Carlsbad, CA, USA) containing 2 m[m]{.smallcaps} glutamine, 10% heat-inactivated foetal bovine serum (Fisher Biotec, Wembley, WA, Australia), 10% dimethyl sulphoxide and 50 U ml^−1^ penicillin and 50 μg ml^−1^ streptomycin. Peripheral blood mononuclear cells were thawed, washed in RPMI with 2% foetal bovine serum and incubated for 30 min in RPMI with 2% foetal bovine serum, 10 m[m]{.smallcaps} HEPES, 1 m[m]{.smallcaps} magnesium chloride and 100 U ml^−1^ DNase I (Roche, Sydney, NSW, Australia). Antibodies used were: mAb to CD19-BV421 (HIB19), CD3-PE (UCHT1) and CD4-BV570 (RPA-T4) from BioLegend (San Diego, CA, USA); CD14-PerCP (MφP9), CD56-PECy-7 (NCAM16.2), CD8-BV650 (RPA-T8), CD45RO-APC-H7 (UCHL1), T-Bet-Alexa Fluor 647 (4B10) and corresponding isotype control (IgG~1~) from BD Biosciences (San Jose, CA, USA); Eomes-FITC (WD1928) and corresponding isotype control (IgG~1~) from ebioscience (San Diego, CA, USA). Cells were blocked with mouse IgG (33 μg ml^−1^; Life Technologies) and stained for all extracellular antigens except CD14 in Brilliant Stain Buffer (BD Horizon, San Jose, CA, USA). Cells were fixed, permeabilised, blocked in mouse serum and stained for Eomes and T-bet (or corresponding isotype controls) and CD14 using the Foxp3 Staining Buffer Set (ebioscience) according to the manufacturer\'s instructions. Cells were analysed on a Fortessa (BD Biosciences) using the FlowJo software (Tree star Inc., Ashland, OR, USA).

IFNL3 genotyping and gene expression by qPCR
--------------------------------------------

All healthy controls and HCV-infected subjects (summarised in [Table 1](#tbl1){ref-type="table"}) were genotyped for the *rs8099917* and *rs12979860* SNPs by methods reported previously.^[@bib13],\ [@bib47]^

Total RNA was extracted from whole blood in PAXgene tubes using the PAXgene Blood RNA Kit (Qiagen, Hilden, Germany). The RNeasy Kit (Qiagen, Valencia, CA, USA) was used for immune cell pellets. cDNA was prepared using Superscript III, RNaseOUT, OligodT~12--18\ primer~ and random primers (Life Technologies) in a Mastercycler gradient 5331 (Eppendorf AG, Hamburg, Germany). Reverse transcription was performed at 50 °C for 45 min.

Gene expression was measured by quantitative PCR (qPCR) using custom-designed primers (Sigma-Aldrich, St Louis, MO, USA) specific for *IFNL3* (forward: 5′-CCCAAAAAAGGAGTCCCCTG-3′ and reverse: 5′-GGTTGCATGACTGGCGGA-3′). Specificity for *IFNL3* was confirmed by sequencing of the PCR pro(methods published previously^[@bib13]^). In addition, primers for *IFNLR1* were designed (forward: 5′-CTAAGCCCACCTGCTTCTTG-3′ reverse: 5′-GTCAGTTCCTTTTGGGGACA-3′). These primers detected both splice forms of *IFNLR1*: the membrane-associated and soluble forms. Primers for the membrane-associated (*INLR1-mem*, forward: 5′-CTAAGCCCACCTGCTTCTTG-3′ reverse: 5′-TGTCCCCAAAAGGAACTGAC-3′) and soluble receptor (*INLR1-sol*, forward: 5′-CTAAGCCCACCTGCTTCTTG-3′ reverse: 5′-TGTCCCCAAAAGGAACTGAC-3′) were also designed.^[@bib13]^ *MxA* (forward: 5′-GCCGGCTGTGGATATGCTA-3′ reverse: 5′-TTTATCGAAACATCTGTGAAAGCAA-3′) was selected as the candidate ISG given published associations with HCV treatment outcomes.^[@bib48]^ *GAPDH* primers (forward: 5′-TCCACCACCCTGTTGCTGTA-3′ reverse: 5′-ACCACAGTCCAGCCATCAC-3′) were used as the housekeeping gene. Amplification was measured using Power SYBR Green PCR Master Mix (Life Technologies). Gel electrophoresis was used to confirm the absence of gDNA products from the PCR reactions. Expression was measured using *C*~T~ values, normalised to that of *GAPDH* (Δ*C*~T~=*C*~T~ (*GAPDH*)−*C*~T~ (target) and then expressed as 2^−Δ*C*~T~^. *C*~T~ values were \<30, and all amplifications were carried out in duplicate. Transcription factor expression was assessed using Taqman Gene Expression assays from Applied Biosystems (Carlsbad, CA, USA).

Statistics
----------

Baseline and 4-week data for various demographic, haematological, biochemical and virological characteristics are expressed as mean±s.d. The difference between *IFNL3* genotypes was assessed by *χ*^2^ test or *t*-test where appropriate. qPCR data were transformed for normality (log(*Y* × 10^6^). Pearson\'s *R* coefficient was used to determine the correlation between samples. Transcription factor expression levels across the samples were ranked, and the ratio of the ranks was compared. A two-sided *P*-value \<0.05 was considered significant.
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![Flow cytometric analysis of immune cell subsets in CHC by *rs12979860* genotype (*n=*67). (**a**) Percentage of major immune cell subsets (*P\<*0.05 for monocytes and *P*=0.05 for CD8s). (**b**) Ratio of CD56 high to CD56 low cells (*P\<*0.05). (**c**) Ratio of CD4/CD8 (*P*⩽0.05). (**d**) Ratio of CD45RO− to RO+ for CD4 (*P\<*0.001) and CD8 (*P=*0.08) cells.](gene201627f1){#fig1}

![Transcription factor expression by qPCR in peripheral blood from HCV-infected patients (*n=*24) compared with controls (*n=*22). FOXP3 was significantly higher (*P=*0.04) in CHC cohort compared with healthy controls.](gene201627f2){#fig2}

![Expression of transcription factor ratios in the peripheral blood of HCV-treated subjects (*n*=24) analysed for differences in *IFNL3* genotype. (**a**) Ratios show a *TBX21* (Th1/NK)-dominant effect associated with the *IFNL3* responder genotype (*rs8099917* TT and *rs12979860* CC). (**b**) Ratio of *TBX21*/*GATA3* (Th1, NK/Th2) showing significant differences for *rs8099917* (*P=*0.017) and for *rs12979860 (P=*0.038). (**c**) Ratio of *TBX21/RORC* (Th1, NK/Th17) showing significant differences for *rs8099917* (*P=*7.4 × 10^−3^).](gene201627f3){#fig3}

![*IFNL3*, *IFNLR1, IFNLR1-mem*, *IFNLR1-sol* and *MxA* expression by qPCR in peripheral blood from healthy controls (*n*=22) and untreated HCV-infected patients (*n=*24). Significantly higher expression of (**b**) *IFNLR1* (*P=*3.2 × 10^−12^), (**c**) *IFNLR1-mem* (*P=*0.041) and (**d**) *IFNLR1-sol* (*P=*3.0 × 10^−3^) and (**e**) *MxA* (*P=*3.0 × 10^−6^) in the HCV-infected individuals is demonstrated. No difference in (**a**) *IFNL3* expression between controls and HCV subjects in peripheral blood was detected and for *rs12979860* (**e**) at *T*~0~ (*P=*5.2 × 10^−3^). (**c** and **f**) Ratio of *TBX21/FOXP3* (Th1:Treg) showing significant differences for *rs8099917* (**c**) at *T*~0~ (*P=*0.036) and *T*~4w~ (*P=*0.018).](gene201627f4){#fig4}

![Summary of the three cohorts included in this study.](gene201627f5){#fig5}

###### Demographic and baseline haematological parameters according to *IFNL3* genotype in 400 Caucasian patients with chronic hepatitis C

                          Rs8099917          P-*value*              Rs12979860     P-*value*                             
  ----------------------- ------------------ ------------------ ------------------ ----------------- ------------------- ------------------
  *n* (%)                 194 (49)           206 (51)                  ---         133 (33)          267 (67)                   ---
  Sex M:F (%)             110:84 (57):(43)   124:82 (60):(40)          0.48        86:47 (65):(34)   148:119 (55):(45)          0.08
  Age (years)             49.7±9.8           51.1±11.8                 0.17        49.3±10.3         51.0±11.3                  0.13
  Hb (g l^−1^)            147±12             151±14                 **0.011**      149±12            149±14                     0.56
  Platelet ( × 10^9^/l)   217±66             224±65                    0.34        214±61            224±67                     0.12
  WBC ( × 10^9^/l)        6.5±1.8            7.2±2.0             **2.8 × 10^−4^**  5.65±1.9          7.1±1.9              **2.8 × 10^−3^**
  ANC ( × 10^9^/l)        3.7±1.4            4.0±1.5                **0.013**      3.6±1.5           4.0±1.4                 **0.022**
  ALC ( × 10^9^/l)        2.2±0.6            2.4±0.8             **5.0 × 10^−3^**  2.2±0.7           2.3±0.8                 **0.015**
  AMC ( × 10^9^/l)        0.40±0.15          0.45±0.18           **6.1 × 10^−4^**  0.40±0.14         0.44±0.17               **0.021**

Abbreviations: ALC, absolute lymphocyte count; AMC, absolute monocyte count; ANC, absolute neutrophil count; Hb, haemoglobin; WBC, white blood cell. The *P*-values in bold are statistically significant (\<0.05).

###### Haematological parameters according to low or high pre-treatment HCV viral load

                              *Viral load \<8.5 × 10*^*5*^ *IU ml*^−1^   *Viral load* ⩾*8.5 × 10*^*5 *^*IU ml*^−1^      P-*value*
  --------------------------- ------------------------------------------ ------------------------------------------- ----------------
  *Rs8099917* TT:TG/GG (%)    32(35):59(65)                              49(61):31(39)                                **7 × 10^−4^**
  *Rs12979860* CC:CT/TT (%)   15(16):76(84)                              40(50):40(50)                                 **\<0.0001**
  Hb (g l^−1^)                148±13                                     149±13                                            0.38
  Platelet ( × 10^9^/l)       209±54                                     191±60                                            0.12
  WBC ( × 10^9^/l)            6.6±1.9                                    6.1±1.4                                        **0.034**
  ANC ( × 10^9^/l)            3.6±1.4                                    3.4±1.0                                           0.19
  ALC ( × 10^9^/l)            2.4±0.7                                    2.1±0.7                                        **0.034**
  AMC ( × 10^9^/l)            0.45±0.19                                  0.41±0.14                                         0.14

Abbreviations: ALC, absolute lymphocyte count; AMC, absolute monocyte count; ANC, absolute neutrophil count; Hb, haemoglobin; WBC, white blood cell. The *P*-values in bold are statistically significant (\<0.05).
